Fan Jian-Wen, Xu Su-Yi, Wu Jun, Yu Yong-Wei
Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
Department of Outpatient Care, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
World J Diabetes. 2025 Jun 15;16(6):106884. doi: 10.4239/wjd.v16.i6.106884.
An article recently published in the , provides valuable insights into using immune biomarkers to identify renal damage in pediatric patients with newly diagnosed type 1 diabetes (T1D). Although these findings are promising, clinical translation of these immune markers into routine diagnostics and preventive care remains challenging. In this letter, we propose building on the authors' work by exploring the integration of immune biomarkers into a more comprehensive dynamic risk stratification model for early renal injury. Combining immune system indicators with metabolic and genetic factors could enhance the predictive accuracy and support more personalized interventions. Longitudinal studies are needed to evaluate temporal changes in immune biomarkers and their association with long-term renal outcomes in children with T1Ds. Immunomodulatory therapies targeting early immune dysfunction can prevent or slow the progression of diabetic nephropathy. By incorporating these aspects, we hope to translate immune biomarkers from research into practical clinical tools, ultimately improving patient outcomes and reducing the burden of kidney-related complications in pediatric diabetes.
最近发表在《 》上的一篇文章，为利用免疫生物标志物识别新诊断的 1 型糖尿病（T1D）儿科患者的肾脏损伤提供了宝贵见解。尽管这些发现很有前景，但将这些免疫标志物转化为常规诊断和预防护理仍具有挑战性。在这封信中，我们建议在作者工作的基础上，探索将免疫生物标志物整合到一个更全面的早期肾损伤动态风险分层模型中。将免疫系统指标与代谢和遗传因素相结合，可以提高预测准确性，并支持更个性化的干预措施。需要进行纵向研究，以评估免疫生物标志物的时间变化及其与 T1D 儿童长期肾脏结局的关联。针对早期免疫功能障碍的免疫调节疗法可以预防或减缓糖尿病肾病的进展。通过纳入这些方面，我们希望将免疫生物标志物从研究转化为实用的临床工具，最终改善患者结局，减轻儿科糖尿病患者肾脏相关并发症的负担。
